Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
62.1 USD | -3.00% | -4.86% | -25.62% |
05-09 | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
05-08 | Cytokinetics Q1 Net Loss Narrows, Revenue Declines | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.62% | 6.51B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market